An analysis of over 3000 psoriasis patients concluded that adiponectin, an anti-inflammatory adipokine, presented decreased levels in the psoriasis patients with concomitant overweight/obesity, diabetes, or metabolic syndrome [41]. Here, ADIPOQ is linked to obesity disorder.